Qualitätssicherung in der PREOPANC-Studie (2012-003181-40) für die präoperative Radiochemotherapie beim Pankreaskarzinom: Der „dummy run“

Eva Versteijne, Eelco Lens, Astrid van der Horst, Arjan Bel, Jorrit Visser, Cornelis J. A. Punt, Mustafa Suker, Casper H. J. van Eijck, Geertjan van Tienhoven

Research output: Contribution to journalArticleProfessional

Abstract

Background: The Dutch Pancreatic Cancer Group initiated the national, multicentre, controlled PREOPANC trial, randomising between preoperative radiochemotherapy and direct explorative laparotomy for patients with (borderline) resectable pancreatic cancer. The aim of this dummy run is to evaluate compliance with the radiotherapy protocol of this trial, and the quality of delineation and radiation plans. Methods: Eleven radiation oncology departments open for accrual of patients in the PREOPANC trial were provided with all necessary information of a selected ‘dummy’ patient. Each institute was asked to delineate the target volumes, including gross tumour volume, internal gross tumour volume (iGTV), internal clinical target volume, and planning target volume. The institutions were also asked to provide a radiation treatment plan in accordance with the PREOPANC trial protocol. Results: The range of the iGTV was 19.3–77.2 cm3 with a mean iGTV of 41.5 cm3 (standard deviation 14.8 cm3). Nine institutions made a treatment plan using an arc technique for treatment delivery, one an intensity modulated technique and one a 3-field conformal technique. All institutions reached the prescribed target coverage, without exceeding the organs at risk constraints. The institution with the 3‑field conformal technique was advised to use a more sophisticated technique (e. g. volumetric modulated arc therapy) to reduce the dose to the spinal cord. Conclusion: All institutions showed acceptable deviations from the PREOPANC trial protocol and achieved an acceptable quality of delineation and radiation technique. All institutions were allowed to continue participation in the PREOPANC trial.
Original languageGerman
Pages (from-to)630-638
JournalStrahlentherapie und Onkologie
Volume193
Issue number8
DOIs
Publication statusPublished - 2017
Externally publishedYes

Cite this

Versteijne, Eva ; Lens, Eelco ; van der Horst, Astrid ; Bel, Arjan ; Visser, Jorrit ; Punt, Cornelis J. A. ; Suker, Mustafa ; van Eijck, Casper H. J. ; van Tienhoven, Geertjan. / Qualitätssicherung in der PREOPANC-Studie (2012-003181-40) für die präoperative Radiochemotherapie beim Pankreaskarzinom: Der „dummy run“. In: Strahlentherapie und Onkologie. 2017 ; Vol. 193, No. 8. pp. 630-638.
@article{c62144abf9b84ac7ae68d03f0d3a3f85,
title = "Qualit{\"a}tssicherung in der PREOPANC-Studie (2012-003181-40) f{\"u}r die pr{\"a}operative Radiochemotherapie beim Pankreaskarzinom: Der „dummy run“",
abstract = "Background: The Dutch Pancreatic Cancer Group initiated the national, multicentre, controlled PREOPANC trial, randomising between preoperative radiochemotherapy and direct explorative laparotomy for patients with (borderline) resectable pancreatic cancer. The aim of this dummy run is to evaluate compliance with the radiotherapy protocol of this trial, and the quality of delineation and radiation plans. Methods: Eleven radiation oncology departments open for accrual of patients in the PREOPANC trial were provided with all necessary information of a selected ‘dummy’ patient. Each institute was asked to delineate the target volumes, including gross tumour volume, internal gross tumour volume (iGTV), internal clinical target volume, and planning target volume. The institutions were also asked to provide a radiation treatment plan in accordance with the PREOPANC trial protocol. Results: The range of the iGTV was 19.3–77.2 cm3 with a mean iGTV of 41.5 cm3 (standard deviation 14.8 cm3). Nine institutions made a treatment plan using an arc technique for treatment delivery, one an intensity modulated technique and one a 3-field conformal technique. All institutions reached the prescribed target coverage, without exceeding the organs at risk constraints. The institution with the 3‑field conformal technique was advised to use a more sophisticated technique (e. g. volumetric modulated arc therapy) to reduce the dose to the spinal cord. Conclusion: All institutions showed acceptable deviations from the PREOPANC trial protocol and achieved an acceptable quality of delineation and radiation technique. All institutions were allowed to continue participation in the PREOPANC trial.",
author = "Eva Versteijne and Eelco Lens and {van der Horst}, Astrid and Arjan Bel and Jorrit Visser and Punt, {Cornelis J. A.} and Mustafa Suker and {van Eijck}, {Casper H. J.} and {van Tienhoven}, Geertjan",
year = "2017",
doi = "10.1007/s00066-017-1153-6",
language = "German",
volume = "193",
pages = "630--638",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "8",

}

Qualitätssicherung in der PREOPANC-Studie (2012-003181-40) für die präoperative Radiochemotherapie beim Pankreaskarzinom: Der „dummy run“. / Versteijne, Eva; Lens, Eelco; van der Horst, Astrid; Bel, Arjan; Visser, Jorrit; Punt, Cornelis J. A.; Suker, Mustafa; van Eijck, Casper H. J.; van Tienhoven, Geertjan.

In: Strahlentherapie und Onkologie, Vol. 193, No. 8, 2017, p. 630-638.

Research output: Contribution to journalArticleProfessional

TY - JOUR

T1 - Qualitätssicherung in der PREOPANC-Studie (2012-003181-40) für die präoperative Radiochemotherapie beim Pankreaskarzinom: Der „dummy run“

AU - Versteijne, Eva

AU - Lens, Eelco

AU - van der Horst, Astrid

AU - Bel, Arjan

AU - Visser, Jorrit

AU - Punt, Cornelis J. A.

AU - Suker, Mustafa

AU - van Eijck, Casper H. J.

AU - van Tienhoven, Geertjan

PY - 2017

Y1 - 2017

N2 - Background: The Dutch Pancreatic Cancer Group initiated the national, multicentre, controlled PREOPANC trial, randomising between preoperative radiochemotherapy and direct explorative laparotomy for patients with (borderline) resectable pancreatic cancer. The aim of this dummy run is to evaluate compliance with the radiotherapy protocol of this trial, and the quality of delineation and radiation plans. Methods: Eleven radiation oncology departments open for accrual of patients in the PREOPANC trial were provided with all necessary information of a selected ‘dummy’ patient. Each institute was asked to delineate the target volumes, including gross tumour volume, internal gross tumour volume (iGTV), internal clinical target volume, and planning target volume. The institutions were also asked to provide a radiation treatment plan in accordance with the PREOPANC trial protocol. Results: The range of the iGTV was 19.3–77.2 cm3 with a mean iGTV of 41.5 cm3 (standard deviation 14.8 cm3). Nine institutions made a treatment plan using an arc technique for treatment delivery, one an intensity modulated technique and one a 3-field conformal technique. All institutions reached the prescribed target coverage, without exceeding the organs at risk constraints. The institution with the 3‑field conformal technique was advised to use a more sophisticated technique (e. g. volumetric modulated arc therapy) to reduce the dose to the spinal cord. Conclusion: All institutions showed acceptable deviations from the PREOPANC trial protocol and achieved an acceptable quality of delineation and radiation technique. All institutions were allowed to continue participation in the PREOPANC trial.

AB - Background: The Dutch Pancreatic Cancer Group initiated the national, multicentre, controlled PREOPANC trial, randomising between preoperative radiochemotherapy and direct explorative laparotomy for patients with (borderline) resectable pancreatic cancer. The aim of this dummy run is to evaluate compliance with the radiotherapy protocol of this trial, and the quality of delineation and radiation plans. Methods: Eleven radiation oncology departments open for accrual of patients in the PREOPANC trial were provided with all necessary information of a selected ‘dummy’ patient. Each institute was asked to delineate the target volumes, including gross tumour volume, internal gross tumour volume (iGTV), internal clinical target volume, and planning target volume. The institutions were also asked to provide a radiation treatment plan in accordance with the PREOPANC trial protocol. Results: The range of the iGTV was 19.3–77.2 cm3 with a mean iGTV of 41.5 cm3 (standard deviation 14.8 cm3). Nine institutions made a treatment plan using an arc technique for treatment delivery, one an intensity modulated technique and one a 3-field conformal technique. All institutions reached the prescribed target coverage, without exceeding the organs at risk constraints. The institution with the 3‑field conformal technique was advised to use a more sophisticated technique (e. g. volumetric modulated arc therapy) to reduce the dose to the spinal cord. Conclusion: All institutions showed acceptable deviations from the PREOPANC trial protocol and achieved an acceptable quality of delineation and radiation technique. All institutions were allowed to continue participation in the PREOPANC trial.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85020698829&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/28608305

U2 - 10.1007/s00066-017-1153-6

DO - 10.1007/s00066-017-1153-6

M3 - Article

VL - 193

SP - 630

EP - 638

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 8

ER -